v3.26.1
SHARE-BASED COMPENSATION (Tables)
 9 Months Ended
Apr. 30, 2026
Defined Benefit Plan Disclosure [Line Items]  
SUMMARY OF NUMBER OF OPTIONS GRANTED

 

   Number of options  

Weighted

average

exercise price

  

Weighted

average

remaining

contractual term

(in years)

  

Aggregate

intrinsic value

 
                 
Balance as of July 31, 2025   13,251   $896.61    1.62   $      - 
Granted (i)   328,700    6.38    4.70    - 
Expired   (4,477)   636           
Balance as of April 30, 2026   337,474    33.06    4.61    - 
                     
Exercisable as of April 30, 2026   22,912   $403.06    3.15   $- 

 

  (i)

On August 1, 2025, the Company granted 37,700 stock options to employees and members of the scientific advisory board at an exercise price of $12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $218,784. The fair value of options granted during the nine-month period ended April 30, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 116%, expected term of 5.0 years, risk-free interest rate of 3.98%, dividend yield of 0%, and a stock price of $7.50 on the grant date.

 

On February 1, 2026, the Company granted 291,000 stock options to employees and members of the scientific advisory board at an exercise price of $5.59 per share. All options vest in equal quarterly installments over two years, with the first vesting date on May 1, 2026. The options expire on February 1, 2031. The grant-date fair value of the award was $1,031,192. The fair value of options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 123%, expected term of 5.0 years, risk-free interest rate of 3.79%, dividend yield of 0%, and a stock price of $4.30 on the grant date.
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS

 

Exercise

price

  

Options

outstanding

as of

April 30, 2026

  

Weighted

average

remaining

contractual term

(years)

  

Options

exercisable

as of

April 30, 2026

  

Weighted

average

remaining

contractual

term (years)

   Expiry Date
$5.59    291,000    4.75    -    4.75   February 1, 2031
$12.50    37,700    4.25    14,138    4.25   August 1, 2030
$60.00    333    3.70    333    3.70   January 16, 2030
$904.50    2,663    2.14    2,663    2.14   June 20, 2028
$1,074.00    136    1.83    136    1.83   February 27, 2028
$907.97    1,195    1.26    1,195    1.26   August 2, 2027
$706.50    206    1.06    206    1.06   May 20, 2027
$1,126.50    1,000    0.79    1,000    0.79   February 16, 2027
$1,270.50    3,160    0.75    3,160    0.75   January 13, 2027
$1,074.83    81    0.50    81    0.50   November 1, 2026
      337,474         22,912         
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED

The following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for nine-month period ended April 30, 2026:

 

   Number of     
   RSU’s   Aggregate 
   outstanding   intrinsic value 
Balance, July 31, 2025   -   $- 
Granted (i)   40,000    376,000 
Balance, April 30, 2026   40,000   $167,200 

 

  (i)

On September 24, 2025, the Company granted 40,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on the earlier of September 23, 2028 or the occurrence of a change of control, resignation, or dismissal without cause. The grant-date fair value of these RSUs was $376,000.
SCHEDULE OF BRIAPRO RESTRICTED STOCK UNITS GRANTED

The following table summarizes the number of BriaPro RSU’s granted to directors under the Omnibus Plan for the nine-month period ended April 30, 2026:

 

   Number of     
   RSU’s   Aggregate 
   outstanding   intrinsic value 
Balance, July 31, 2025   19,200   $700 
Granted (i)   7,189,000    262,399 
Balance, April 30, 2026   7,208,200   $263,099 

 

  (i)

On April 1, 2026, BriaPro granted 7,189,000 RSUs to directors under the Omnibus Plan. These RSUs vest in full on April 1, 2027. The grant-date fair value of these RSUs was $262,399, based on a grant-date fair value of $0.0365 per RSU.
SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED

The following table summarizes the number of PSU’s granted under the Omnibus Plan for nine-month period ended April 30, 2026:

 

   Number of     
   PSU’s   Aggregate 
   outstanding   intrinsic value 
Balance, July 31, 2025   -   $- 
Granted (i)   165,935    1,434,513 
Balance, April 30, 2026   165,935   $693,608 

 

  (i)

On August 1, 2025, the Company granted 65,935 performance-based stock units (“PSUs”) to the Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), Chief Medical Officer (“CMO”), and Chief Scientific Officer (“CSO”) under the Omnibus Plan. These PSUs contain performance conditions tied to the advancement of the Company’s Bria-IMT Phase 3 program, the Bria-OTS program, and certain corporate and governance objectives. The grant-date fair value of the PSUs awarded to these officers totaled $353,228. The PSUs awarded to the CMO and CSO include milestones related to the Bria-OTS program, with grant-date fair values of $70,643 each. The CFO’s PSUs relate to corporate and financial reporting objectives, with a grant-date fair value of $70,643.

 

On September 24, 2025, the Company granted 100,000 PSUs to a director under the Omnibus Plan. These PSUs contain performance conditions related to the Company’s corporate, strategic, and governance objectives. The grant-date fair value of this award was $940,000, determined using the closing price of the Company’s common stock on the grant date.

 

The fair value of all PSU awards was determined using the closing price of the Company’s common stock on the respective grant dates. In accordance with ASC 718, management evaluates the probability of achieving each performance condition at each reporting date. As of April 30, 2026, management has determined that achievement of the applicable performance conditions remains probable. Compensation cost is recognized over the requisite service period on a graded vesting (tranche-by-tranche) basis.

 

During the nine-month period ended April 30, 2026, the Company achieved the performance condition related to the CFO’s PSU’s. As a result 3,532 PSUs granted to the CFO vested and became issuable during the period.
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES

 

   2026   2025   2026   2025 
   Three months ended
April 30,		   Nine months ended
April 30,		 
   2026   2025   2026   2025 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
Research, development, and clinical trial expenses  $175,999    36,493   $338,446    120,050 
General and administrative expenses   256,208    188,322    674,303    656,829 
Total share-based compensation  $432,207    224,815   $1,012,749    776,879 
BriaPro Therapeutics Corp, [Member]  
Defined Benefit Plan Disclosure [Line Items]  
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS

 

Exercise

Price

  

Options

outstanding

as of

April 30, 2026

  

Options

exercisable

as of

April 30, 2026

   Expiry Date
             
$0.0933    400,000    400,000   June 20, 2028
$0.1108    21,000    21,000   February 27, 2028
$0.0984    180,100    180,100   August 2, 2027
$0.0729    31,000    31,000   May 20, 2027
$0.1162    150,000    150,000   February 16, 2027
$0.1310    474,700    474,700   January 13, 2027
$0.1165    12,600    12,600   November 1, 2026
      1,269,400    1,269,400